Tables
- Table 1
Wider benefits of PPI in research
• Identification and clarification of research questions • Ensuring research questions meet patients’ needs • Improving the design, conduct and dissemination of research studies • Ensuring openness, transparency and public accountability • Results in research outcomes that may be better translatable into patient benefit • Improves patient information, resulting in more appropriate and accessible participant information for would-be participants (language/content) • Increasing public confidence in health research • Boosting recruitment • Enhancing learning from experience and good practice • Offering different perspectives to the other team members • Dissemination to wider patient and public audiences - Table 2
Opportunities during this year’s ERS Congress to meet and discuss with patients and members of the public about ongoing PPI in research and future collaborations
Opportunities When? Details “How to involve patients in research” September 30 at 07:00–08:15 h This session will be led by patients who have been involved in the Europe-wide U-BIOPRED severe asthma project and will be chaired by Dan Smyth (ELF Chair), himself a patient Annual reception for the patient organisations attending Congress September 28 at 12:45–14:00 h (D404) If you are interested in coming to meet some of the key patient organisations and advocates in Europe, please send an email to Sarah.Masefield{at}europeanlung.org Patient organisations and ELF stand in the World Village September 26–30 Patient organisations and ELF will display information about their ideas and activities Healthy Lungs for Life Auditorium in the World Village Some patient organisations will be presenting about their opportunities and you should look out for the programme on site and come along to hear more Note that the patient organisation programme is also available on the ERS Congress website (www.erscongress.org).
- Table 3
Difficulties and barriers to PPI
• Creating a gap between PPI group and researchers • Using scientific/very technical language • Personal difficulties (physical/emotional) • Language barriers • Organisational barriers (timing and place of meetings) • Living with illness and caring responsibilities
Vol 11 Issue 3
Table of Contents
How to optimise patient and public involvement in your research
